Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial
Éric Deutsch(Inserm), D. Azria(Inserm), Y. Bécouarn, C. Lemanski, David Malka(Inserm), E. Rio(Institut de Cancérologie de l'Ouest), Thierry Conroy(Inserm), Jean‐Pierre Pignon(Inserm), Laurent Miglianico(Canadian Partnership Against Cancer), Isabelle Martel‐Lafay(Centre Léon Bérard), Béata Juzyna(UniCancer Group), Anne Delarochefordiere(Institut Curie), K. Malekzadeh(Institut Gustave Roussy), Edouard Pâris(Institut Gustave Roussy), P Ezra(Institut Gustave Roussy), Antonin Lévy(Inserm)
Cited by 89
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2010|1.9k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k